Sign In
Buy BMRN
$56.47
+1.81 (+3.31%)
At Close: Jun 04, 2026
BioMarin Announces First Quarter 2021 Financial Results and Corporate Updates
04:03pm, Thursday, 29'th Apr 2021
SAN RAFAEL, Calif., April 29, 2021 /PRNewswire/ -- Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended March 31, 2021 2020 % Change Total Revenues $
Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for
01:32pm, Thursday, 22'nd Apr 2021
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN RAFAEL, Calif., April 15, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) presented new and updated data at the 2021 American College of Medical Genetics and Genomics (ACMG) Annu
BioMarin to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, April 29 at 4:30pm ET
08:30am, Tuesday, 13'th Apr 2021
SAN RAFAEL, Calif., April 13, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host
BioMarin (BMRN) Down 7.7% Since Last Earnings Report: Can It Rebound?
12:41pm, Saturday, 27'th Mar 2021
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?
SAN RAFAEL, Calif., March 20, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that data from the open-label long-term extension of the Phase 3 study of 15 µg/kg dose
BioMarin: One Step Back Before The Jump
05:52am, Monday, 15'th Mar 2021
BMRN's core business value is around $78 per share. Even with conservative assumptions, ValRox represents a significant commercial opportunity.
BioMarin's Hemophilia Gene Therapy Scores RMAT Designation In US
12:05pm, Monday, 08'th Mar 2021
The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) valoctocogene roxaparvovec investigational gene therapy for the treat
Anthem, BioMarin, CRISPR, GE and More Thursday Afternoon Analyst Calls
12:25pm, Thursday, 04'th Mar 2021
With the trading day about halfway over, the broad markets had managed to push higher on the day, despite dipping into the red earlier.
Why Biomarin Pharmaceutical's Stock is Down During Today's Session
09:54am, Friday, 26'th Feb 2021
Biomarin Pharmaceutical (NASDAQ:BMRN) is currently down 7.49% to a price of $78.33. Friday the stock has been traded at a volume of 86.17 thousand, about 7.66% of its recent 30-day volume average of 1
BioMarin Pharmaceutical's (BMRN) CEO J.J. Bienaime on Q4 2020 Results - Earnings Call Transcript
03:47am, Friday, 26'th Feb 2021
BioMarin Pharmaceutical's (BMRN) CEO J.J. Bienaime on Q4 2020 Results - Earnings Call Transcript
Biomarin Pharmaceutical's Earnings Outlook
10:09am, Wednesday, 24'th Feb 2021
Biomarin Pharmaceutical (NASDAQ:BMRN) unveils its next round of earnings this Thursday, February 25. Get prepared with Benzinga's ultimate preview for Biomarin Pharmaceutical's Q4 earnings.
ALXN vs. BMRN: Which Stock Is the Better Value Option?
12:52pm, Thursday, 11'th Feb 2021
ALXN vs. BMRN: Which Stock Is the Better Value Option?
BioMarin's Hemophilia A Treatment: An Assessment
07:24am, Thursday, 04'th Feb 2021
BioMarin received a CRL last August which delayed approval by 2 years. Other competitors may be catching up.
ALXN vs. BMRN: Which Stock Should Value Investors Buy Now?
12:48pm, Tuesday, 26'th Jan 2021
ALXN vs. BMRN: Which Stock Is the Better Value Option?
